Phase I study of napabucasin in combination with FOLFIRI  + bevacizumab in Japanese patients with metastatic colorectal cancer

ConclusionsNapabucasin 240  mg BID in combination with FOLFIRI and bevacizumab was tolerated, with a manageable safety profile in Japanese patients with metastatic CRC.

Source: International Journal of Clinical Oncology - October 23, 2021 Category: Cancer & Oncology Source Type: research